Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS23 in healthy volunteers
NCT03001544Phase 1Unknown
- Sponsor
- Translational Sciences, Inc.
- Start
- Jul 2015
- Primary completion
- Jun 2016
01
Overview
Phase 1, open-label, single-arm trial of TS23 in thrombosis, cerebral ischemia, venous thrombosis and 2 more, sponsored by Translational Sciences, Inc. Primary endpoint: Adverse Events at 10 weeks. Status: unknown.
02
Drugs
TS23
03
Conditions
thrombosiscerebral ischemiavenous thrombosispulmonary embolism (PE)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03001544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001544.